New drug combo shows promise against tough colon cancer
NCT ID NCT06124378
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 32 times
Summary
This study tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before surgery can help shrink tumors in people with a certain type of advanced colon cancer (MSS). About 60 adults aged 18-75 will receive the combination, then have surgery. The main goal is to see how many patients have no cancer cells left in their removed tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.